Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 809 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Neoadjuvant Atezolizumab Plus Chemotherapy Is Safe and Has Promising Activity in... January 11, 2024 EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F) June 1, 2023 Breast Cancer Survivor Shares Inspiring Images Of Herself As “Bold Indian... March 1, 2019 Adjuvant Treatment with Nivolumab Plus Ipilimumab Combination Fails to Improve DFS... February 22, 2023 Load more HOT NEWS Tailored Radiation to Treat Brain Metastases Reduces Impact on Cognitive Function How serendipity sent this oncologist in search of a cure for... FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or... Young Woman’s Breast Cancer Diagnosis Ends Up Saving Her Mom’s Life...
